Skip to main
EXAS

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 13%
Hold 56%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences is poised for continued growth, especially with the anticipated market adoption of its Cologuard test, which is expected to increase from approximately 15% market share to over 40% in the long term. The company has revised its 2025 guidance upward beyond its recent third-quarter performance, driven by strong revenue growth, highlighted by a 22% year-over-year increase in its core screening business. Additionally, the successful launch of the Cancerguard blood test, along with positive Adjusted EBITDA generation, reinforces a promising financial outlook as Exact Sciences aims to triple the number of individuals screened by 2027.

Bears say

Exact Sciences faces several challenges that contribute to a negative outlook on its stock. The company's reliance on promotional marketing for Cologuard, along with a history of net losses, raises concerns about its ability to achieve and sustain GAAP profitability. Additionally, projected revenue estimates for 2027, although potentially conservative, indicate a shortfall from targets, reflecting uncertainty surrounding future sales performance amid anticipated acquisitions and market competition.

Exact Sciences (EXAS) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 13% recommend Buy, 56% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 16 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.